A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus

Trial Profile

A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs GDC 0853 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 05 May 2017 Status changed from not yet recruiting to recruiting.
    • 26 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top